Eli Lilly and Company $LLY Shares Acquired by Values Added Financial LLC

Values Added Financial LLC grew its stake in Eli Lilly and Company (NYSE:LLY) by 3.2% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 914 shares of the company’s stock after acquiring an additional 28 shares during the quarter. Values Added Financial LLC’s holdings in Eli Lilly and Company were worth $712,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. PNC Financial Services Group Inc. increased its position in shares of Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after purchasing an additional 50,002,551 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Eli Lilly and Company during the 1st quarter worth about $4,613,912,000. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after purchasing an additional 4,975,395 shares during the last quarter. Cohen Investment Advisors LLC increased its position in shares of Eli Lilly and Company by 7,975.5% during the 1st quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company’s stock worth $647,225,000 after purchasing an additional 773,947 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its position in shares of Eli Lilly and Company by 106.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock worth $1,154,508,000 after purchasing an additional 765,010 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on LLY. JPMorgan Chase & Co. cut their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, September 16th. Leerink Partnrs downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Guggenheim raised their price objective on Eli Lilly and Company from $875.00 to $948.00 and gave the stock a “buy” rating in a research report on Wednesday. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. Finally, Berenberg Bank restated a “hold” rating and set a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $943.00.

Insiders Place Their Bets

In related news, Director Gabrielle Sulzberger acquired 117 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This represents a 4.52% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jamere Jackson acquired 200 shares of the firm’s stock in a transaction dated Friday, August 8th. The stock was bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the purchase, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $845.55 on Thursday. The stock has a 50-day simple moving average of $738.69 and a 200-day simple moving average of $766.57. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a market capitalization of $800.28 billion, a PE ratio of 55.26, a PEG ratio of 1.18 and a beta of 0.47. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $937.00.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.